临床分离的携带TR34/L98H型的耐唑类药物烟曲霉的耐药机制分析

doi:10.3969/j.issn.1673-8640.2016.09.005

摘要/Abstract

摘要：

目的对临床分离的耐唑类药物烟曲霉菌株进行耐药机制等相关研究。方法自1例侵袭性曲霉病（IA）患者的肺泡灌洗液（BALF）中分离得到1株烟曲霉,采用美国临床实验室标准化协会（CLSI）M38-A2微量液基稀释法测定伊曲康唑、伏立康唑、泊沙康唑、两性霉素B和卡泊芬净对该菌株的最低抑菌浓度（MIC）/最低有效浓度（MEC）,并对该菌株的唑类药物靶酶基因cyp51A进行克隆和序列测定分析,扩增并检测该菌株的9个微卫星标记位点,将其与国际上已经报告的具有相同耐药基因型的烟曲霉菌株进行非加权配对算术平均法（UPGMA）聚类分析。结果伊曲康唑、伏立康唑、泊沙康唑、两性霉素B对该菌株的MIC分别为>16、2、0.5和2 μg/mL,卡泊芬净对该菌株的MEC为0.25 μg/mL。该菌株的cyp51A基因序列中存在启动子区-288~-322位间34 bp串联序列的插入,以及编码区T364A、T960A、T1554A的点突变,分别导致所编码蛋白98位、297位及495位氨基酸的置换（TR34/L98H/S297T/F495I）。微卫星分析显示,该菌株的微卫星分型与先前欧洲国家、亚洲其他国家分离的TR34/L98H/S297T/F495I型菌株不同。结论我们从1例IA患者BALF中分离到对唑类药物耐药的烟曲霉临床菌株,其耐药性是由cyp51A基因启动子区34 bp的串联序列插入结合基因编码区突变所致98位、297位及495位氨基酸置换（TR34/L98H/S297T/F495I）所介导,该菌株是中国所特有的、不同于国际上已描述的对唑类药物耐药的病原性烟曲霉。

关键词: 唑类药物, 耐药, 烟曲霉, cyp51A

Abstract:

Objective To investigate the mechanism of azole resistance in Aspergillus fumigatus. Methods An isolate of Aspergillus fumigatus was collected from bronchoalveolar lavage fluid（BALF） of a patient with invasive aspergillosis（IA）. By microbroth dilution,the minimal inhibitory concentrations（MIC）/minimal effective concentration（MEC） of itraconazole,voriconazole,posaconazole and amphotericin B and caspofungin were determined according to the Clinical and Laboratory Standards Institute（CLSI） M38-A2. The full-length region of the gene encoding the target enzyme of azoles（cyp51A gene including its promoter） was cloned and sequenced. Microsatellite genotyping was performed by amplifying and determining the isolate's 9 microsatellite loci,and the genetic relationships among isolates with the same genotype were then established by cluster analysis using unweighted pair-group method with arithmetic means（UPGMA）. Results For this isolate,the MIC of itraconazole,voriconazole,posaconazole and amphotericin B were >16,2,0.5 and 2 μg/mL. The MEC of caspofungin was 0.25 μg/mL. The sequence analysis of cyp51A gene showed the presence of 2 copies （-288--322）of a 34 bp sequence in tandem in the promoter of cyp51A gene together with the presence of 3 point mutations at T364A,T960A and T1554A,which were accordingly deduced amino acid substitution including TR34/L98H/S297T/F495I. Microsatellite genotyping indicated that this isolate had a unique genotype being different to those reported previously in Europe and Asia. Conclusions The azole-resistant isolate of Aspergillus fumigatus from BALF harboring amino acid substitution TR34/L98H/S297T/F495I has been isolated with a unique genotype being different to isolates reported before.

Key words: Azoles, Drug resistance, Aspergillus fumigatus, cyp51A

中图分类号:

R446.5

王千, 陈伟, 万喆, 李若瑜, 刘伟. 临床分离的携带TR34/L98H型的耐唑类药物烟曲霉的耐药机制分析[J]. 检验医学, 2016, 31(9): 755-760.

WANG Qian, CHEN Wei, WAN Zhe, LI Ruoyu, LIU Wei. Mechanism of azole resistance in Aspergillus fumigatus with TR34/L98H mutations[J]. Laboratory Medicine, 2016, 31(9): 755-760.

图/表 4

参考文献 19

1	WALSH TJ,ANAISSIE EJ,DENNING DW,et al.Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis,2008,46(3):327-360.
2	VERMEULEN E,LAGROU K,VERWEIJ PE.Azole resistance in Aspergillus fumigatus:a growing public health concern[J]. Curr Opin Infect Dis,2013,26(6):493-500.
3	SAMSON RA,VISAGIE CM,HOUBRAKEN J,et al.Phylogeny,identification and nomenclature of the genus Aspergillus[J]. Stud Mycol,2014,78:141-173.
4	HONG SB,GO SJ,SHIN HD,et al.Polyphasic taxonomy of Aspergillus fumigatus and related species[J]. Mycologia,2005,97(6):1316-1329.
5	Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi[S]. M38-A2,CLSI,2008.
6	DE VALK HA,MEIS JF,CURFS IM,et al.Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates[J]. J Clin Microbiol,2005,43(8):4112-4120.
7	MELLADO E,DIAZ-GUERRA TM,CUENCA-ESTRELLA M,et al.Identification of two different 14-alpha sterol demethylase-related genes(cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species[J]. J Clin Microbiol,2001,39(7):2431-2438.
8	CHOWDHARY A,SHARMA C,KATHURIA S,et al.Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi,India and an update of the situation in Asia[J]. Front Microbiol,2015,6:428.
9	LOCKHART SR,FRADE JP,ETIENNE KA,et al.Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene[J]. Antimicrob Agents Chemother,2011,55(9):4465-4468.
10	VERWEIJ PE,HOWARD SJ,MELCHERS WJ,et al.Azole-resistance in Aspergillus:proposed nomenclature and breakpoints[J]. Drug Resist Updat,2009,12(6):141-147.
11	ESPINEL-INGROFF A,FOTHERGILL A,FULLER J,et al.Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method(M38-A2 document)[J]. Antimicrob Agents Chemother,2011,55(6):2855-2859.
12	SNELDERS E,VAN DER LEE HA,KUIJPERS J,et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism[J]. PLoS Med,2008,5(11):e219.
13	SNELDERS E,CAMPS SM,KARAWAJCZYK A,et al.Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus[J]. PLoS One,2012,7(3):e31801.
14	PRIGITANO A,VENIER V,COGLIATI M,et al.Azole-resistant Aspergillus fumigatus in the environment of northern Italy,May 2011 to June 2012[J]. Euro Surveill,2014,19(12):20747.
15	ZMERDIVEN GE,AK S,ENER B,et al.First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey[J]. J Infect Chemother,2015,21(8):581-586.
16	WIEDERHOLD NP,GIL VG,GUTIERREZ F,et al.First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States[J]. J Clin Microbiol,2016,54(1):168-171.
17	LIU M,ZENG R,ZHANG L,et al.Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China[J]. Antimicrob Agents Chemother, 2015,59(7):4321-4325.
18	孙毅,刘伟,陈伟,等. 对唑类药物交叉耐药的烟曲霉临床分离株耐药机制的初步探讨[J]. 中华皮肤科杂志,2011,44(4):244-248.
19	CAMPS SM,RIJS AJ,KLAASSEN CH,et al.Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism[J]. J Clin Microbiol, 2012,50(8):2674-2680.

引物名称	序列（5'~ 3'）	用途
ITS1	TCCGTAGGTGAACCTGCGG	扩增烟曲霉ITS区
ITS4	TCCTCCGCTTATTGATATGC
Actin F	ATGTGCAAGGCCGGTTTCGC	扩增烟曲霉肌动蛋白区
Actin R	TACGAGTCCTTCTGGCCCAT
Calmo F	CCGAGTACAAGGAGGCCTTC	扩增烟曲霉钙调蛋白区
Calmo R	CCGATAGAGGTCATAACGTGG
β-tub1	AATTGGTGCCGCTTTCTGG	扩增烟曲霉β-微管蛋白区
β-tub2	AGTTGTCGGGACGGAATAG
Cyp51-P1	ATATATACGTCGATCTGTGTGACACCAC	扩增烟曲霉cyp51A基因启动子区及编码区
Cyp51-P2	TCACTTGGATGTGTTTTTCGACCGC

引物名称	序列（5'~ 3'）	用途
ITS1	TCCGTAGGTGAACCTGCGG	扩增烟曲霉ITS区
ITS4	TCCTCCGCTTATTGATATGC
Actin F	ATGTGCAAGGCCGGTTTCGC	扩增烟曲霉肌动蛋白区
Actin R	TACGAGTCCTTCTGGCCCAT
Calmo F	CCGAGTACAAGGAGGCCTTC	扩增烟曲霉钙调蛋白区
Calmo R	CCGATAGAGGTCATAACGTGG
β-tub1	AATTGGTGCCGCTTTCTGG	扩增烟曲霉β-微管蛋白区
β-tub2	AGTTGTCGGGACGGAATAG
Cyp51-P1	ATATATACGTCGATCTGTGTGACACCAC	扩增烟曲霉cyp51A基因启动子区及编码区
Cyp51-P2	TCACTTGGATGTGTTTTTCGACCGC

菌株	MIC				卡泊芬净MEC
菌株	伊曲康唑	伏立康唑	泊沙康唑	两性霉素B	卡泊芬净MEC
BMU11683	>16	2	0.5	2	0.25
AF293	0.25	1	0.125	2	0.25

菌株	MIC				卡泊芬净MEC
菌株	伊曲康唑	伏立康唑	泊沙康唑	两性霉素B	卡泊芬净MEC
BMU11683	>16	2	0.5	2	0.25
AF293	0.25	1	0.125	2	0.25

[1]	缪星国, 叶慧, 苏菲菲. GeneXpert MTB/RIF检出量与结核分枝杆菌培养和利福平表型耐药的关系[J]. 检验医学, 2023, 38(9): 874-877.
[2]	王朝, 赵煜. 持留菌形成机制和清除策略研究进展[J]. 检验医学, 2023, 38(8): 790-795.
[3]	朱昱蓉, 张丹, 贺雅星, 李晶晶, 黄晶, 李婷, 刘鹏, 刘荣华. 肺炎克雷伯菌临床分离株分子分群和流行病学特征[J]. 检验医学, 2023, 38(5): 435-440.
[4]	马冬梅, 蒋东葵, 相晓波, 李世亮. 板蓝根等4种中药单用和与西药联用对广泛耐药鲍曼不动杆菌的抑菌作用[J]. 检验医学, 2023, 38(5): 441-445.
[5]	方咏梅, 章燕, 徐雪莹, 钟峰. 金黄色葡萄球菌耐药性与耐药基因和毒力基因的相关性[J]. 检验医学, 2023, 38(4): 357-361.
[6]	王佳玮, 朱威南, 陈颖盈, 季萍, 王颖. 血培养分离碳青霉烯类耐药肺炎克雷伯菌临床分布和耐药基因分析[J]. 检验医学, 2023, 38(4): 362-367.
[7]	邓劲, 刘雅, 吴思颖, 廖全凤, 张为利, 肖玉玲, 谢轶, 马莹, 康梅. 抗菌药物体外联合药物敏感性试验方法[J]. 检验医学, 2023, 38(4): 385-393.
[8]	任燕飞, 张敏, 杨涛, 李荣凯, 梁新. 呼吸重症科患者下呼吸道感染病原菌流行病学分析[J]. 检验医学, 2023, 38(2): 157-162.
[9]	陈庆, 徐蓉, 孙景勇. 上海地区支气管扩张症患者铜绿假单胞菌耐药机制和分子流行病学特征[J]. 检验医学, 2023, 38(11): 1020-1025.
[10]	邓晨, 戴家泽, 邱丽红, 沈威廷, 蔡木发, 罗文英. 湛江地区高毒力肺炎克雷伯菌分子流行特征[J]. 检验医学, 2023, 38(11): 1026-1031.
[11]	茹浩浩, 陈连勇, 杨星, 陈涛, 闫双群, 许琳. Xpert MTB/RIF与结核分枝杆菌利福平耐药表型检测一致性分析[J]. 检验医学, 2023, 38(11): 1032-1035.
[12]	田媛媛, 贾雄飞. 肠球菌的有益性和致病性[J]. 检验医学, 2023, 38(11): 1101-1105.
[13]	杨思敏, 轩乾坤, 羽晓瑜, 温冬华, 李广波. 国产某品牌大肠埃希菌和肺炎克雷伯菌及3种碳青霉烯耐药基因试剂性能验证[J]. 检验医学, 2023, 38(1): 56-59.
[14]	朱丰村, 曾云祥, 金晓立, 曾添, 黄天鹏, 林枝, 周林双. 204株碳青霉烯类耐药肠杆菌目细菌耐药性分析[J]. 检验医学, 2023, 38(1): 60-65.
[15]	王粟, 丁立, 姜文容, 缪应新, 张艳梅, 赵虎. 高毒力肺炎克雷伯菌耐药性和治疗策略研究进展[J]. 检验医学, 2023, 38(1): 81-86.